Publications

Peer-Reviewed Publications Relating to the Development and Therapeutic Use of EP67

 

  1. Sanderson SD, Kirnarsky L, Sherman, SA, Ember JA, and Taylor SM. Decapeptide Agonists of Human C5a: The Relationship Between Conformation and Spasmogenic and Platelet Aggregatory Activities. J. Med. Chem. 37:3171‑3180, 1994.

 

  1. Sanderson SD, Kirnarsky L, Sherman SA, Vogen SM, Prakash O, Ember JA, Finch AM and Taylor S.M. Decapeptide Agonists of Human C5a: The Relationship between Conformation and Neutrophil Activity. J. Med. Chem. 38:3669‑3675, 1995.

 

  1. Tempero RM, Hollingsworth MA, Burdick MD, Finch AM, Taylor SM, Vogen SM, Morgan EL, and Sanderson SD. Molecular Adjuvant Effects of a Conformationally Biased Agonist of Human C5a Anaphylatoxin. J. Immunol. 158:1377-1382, 1996. PMID: 9013982.

 

  1. Vogen SM, Finch AM, Sherman SA, Kirnarsky L, Taylor SM, and Sanderson SD. Biologically Active Conformer of the Effector Region of Human C5a and the Modulatory Effects of N-Terminal Receptor Binding Determinants on Activity. J. Med. Chem. 40:877-884, 1997.

 

  1. Vogen SM, Prakash O, Kirnarsky L, Sanderson SD, and Sherman SA. NMR Structure of a Potent Decapeptide Agonist of Human C5a Anaphylatoxin. J. Peptide Res. 51:226-234, 1997.

 

  1. Vogen SM, Prakash O, Kirnarsky L, Sanderson SD, and Sherman SA. Determination of Structural Elements Releated to the Biological Activities of Potent Decapeptide Agonists of Human C5a Anaphylatoxin. J. Peptide Res. 54:74-84,1999.

 

  1. Short AJ, Paczkowski NJ, Vogen SM, Sanderson SD, and Taylor SM. Response-Selective C5a Agonists: Differential Effects on Neutropenia and Hypotension in the Rat. Br. J. Pharmacol. 128:511-514, 1999.

 

  1. Ulrich JT, Cieplak W, and Sanderson SD. Induction of an Ag-Specific CTL Response by a Conformationally Biased Agonist of Human C5a Anaphylatoxin as a Molecular Adjuvant.J. Immunol. 164:5492-5498, 2000. PMID: 10799917.

 

  1. Taylor SM, Sherman SA, Kirnarsky L, and Sanderson SD. Development of Response-Selective Agonists of Human C5a Anaphylatoxin: Conformational, Biological, and Therapeutic Considerations. Current Med. Chem. 8:675-684, 2001. PMID: 11281848.

 

  1. Vogen SM, Packowski N, Kirnarsky L,Sherman SA, Taylor SM, and Sanderson SD. Differential Activities of Decapeptide Agonists of Human C5a: The Conformational Effects of Backbone N-Methylation. Int. Immunopharmacol. 1:2151-2162, 2001. PMID: 11710544.

 

  1. Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM. Palmatier MI, and Bevins RA. Immunization to Nicotine with a Peptide-Based Vaccine Composed of a Conformationally Biased Agonist of C5a as a Molecular Adjuvant. Int. Immunopharmacol. 3:137-146, 2003. PMID: 12538044.

 

  1. Hegde GV, Meyers-Clark E, Joshi SS, and Sanderson SD. A Conformationally-Biased Response-Selective Agonist of C5a Acts as a Molecular Adjuvant by Modulating Antigen Processing and Presentation Activities of Human Dendritic Cells. Int. Immunopharmacol. 8:819-827, 2008. PMID: 18442785.

 

  1. Bevins RA, Wilkinson JL, and Sanderson SD. Vaccines to Combat Smoking. Exp. Opin. Biol. Therapy 8:379-383, 2008. PMID: 18352843.

 

  1. Duryee MJ, Bevins RA, Reichel CM, Murray JE, Dong Y, Thiele GM, and Sanderson SD. Immune Responses to Methamphetamine by Active Immunization with Peptide-Based, Molecular Adjuvant-Containing Vaccines. Vaccine 27:2981-2988, 2009. PMID: 19428909.

 

  1. Phillips JA, Morgan EL, Dong Y, Cole GT, McMahan C, Hung CY, and Sanderson SD. Single-Step Conjugation of Bioactive Peptides to Proteins via a Self-Containing Succinimidyl Bis-Arylhydrazone. Bioconjug. Chem. 20:1950-1957, 2009. PMID: 19788175.

 

  1. Morgan EL, Morgan BN, Stein EA, Virts EL, Thoman ML, Sanderson SD, and Phillips JA. Enhancement of In Vivo and In Vitro Immune Functions by a Conformationally Biased, Response-Selective Agonist of Human C5a: Implications for a Novel Adjuvant in Vaccine Design. Vaccine 28:463-469, 2010. PMID: 19836478.

 

  1. Morgan EL, Thoman, ML, Sanderson SD, and Phillips JA. A novel adjuvant for vaccine development in the aged. Vaccine 28:8275-8279, 2010. PMID: 20965299.

 

  1. Kollessera G, Nordgren TM, Mittal AK, Joshi SS, and Sanderson SD. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model. Vaccine 29:5904-5910, 2011. PMID: 21723901.

 

  1. Sheen TR, Cavaco CK, Ebrahimi CM, Thoman ML, Sanderson SD, Morgan EL, and Doran KS. Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. Vaccine 30:9-13, 2011. PMID: 22044742.

 

  1. Hung C-Y, Bellecourt M, Hurgten, B, Sanderson SD, Morgan E, and Cole GT. EP67: A novel peptide adjuvant that enhances protective efficacy of a live, attenuated vaccine against Coccidioides infection. Vaccine 30:4681-4690, 2012. PMID: 22575167.

 

  1. Sanderson SD, Thoman ML, Kis K, Herrera EB, Sepulvida H, and Phillips JA. Innate Immune Induction and Influenza Protection Elicited by a Response-Selective Agonist of Human C5a. PLoS ONE 7:e40303, 2012. PMID: 22792270.

 

  1. Hanke ML, Heim CE, Angle A, Sanderson SD, and Kielian T. Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J. Immunol. 190:2159-2168, 2013 PMID: 23365077.

 

  1. Cavaco CK, Patras KA, Zamal J, Thoman ML, Morgan EL, Sanderson SD, and Doran KS. A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing. Antimicrob. Agents Chemotherap. 57:5492-5499, 2013. PMID: 23979760.

 

  1. Cole GT, Hung C-Y, Sanderson SD, Hurtgen BJ, Wuthrich M, Klein BS, Deepe GS, Ostroff, GR, and Levitz SM. Novel strategies to enhance vaccine immunity against San Joaquin Valley fever. PLoS ONE Pathog., doi/10.1371/journal.ppat.1003768.g001,19 Dec 2013. PMID: 24367252.
Prommune, Inc. © 2017